This is a preview of subscription content, log in via an institution to check access.
Notes
HLH is a life-threatening over-reaction of the immune system characterised by a large release of certain proteins by immune cells into the blood (known as cytokine storm), as well as the accumulation of activated immune cells (i.e. lymphocytes, macrophages) in organs and tissues.
Reference
Health Canada. Summary Safety Review - Opdivo (nivolumab) and Yervoy (ipilimumab) used alone, or in combination. - Health Canada. Internet Document : 24 Jun 2019. Available from: URL: https://hpr-rps.hres.ca/reg-content/summary-safety-review-detail.php?lang=en&linkID=SSR00225
Rights and permissions
About this article
Cite this article
Risk of HLH assessed with Opdivo and Yervoy in Canada. Reactions Weekly 1760, 5 (2019). https://doi.org/10.1007/s40278-019-64164-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-019-64164-9